REPORT HIGHLIGHT
Sexually Transmitted Disease (STD) diagnostics market was valued at USD 156.8 billion by 2019, expanding at 7.9% CAGR during the study period, 2020-2026.
Sexually transmitted diseases (STD) are infectious disease, caused due to person to person sexual contact. It is stated that more than 30 viruses, bacteria, and parasites are transmitted through sexual contact. The infection may develop infections such as Human Immunodeficiency Virus (HIV) infections, syphilis, Neisseria gonorrhoeae (NG), Chlamydia trachomatis (CT), and Trichomonas vaginalis (TV) which causes mild to severe life-threatening symptoms. The infection can transmit person to person, hence STD diagnosis plays a vital role in the prevention and treatment of such conditions. As per the study conducted by the National AIDS Control Organization, early diagnosis of STDs and proper management can help to reduce the HIV-1 infection by 40% to the general population.
Market Dynamics
The increasing prevalence of STDs is considered to be the major driving factor for industry growth. According to the World Health Organization (WHO), more than one million STDs are acquired every year worldwide. Thus, the demand for effective and accurate diagnostic methods is set to increase, driving market growth. Following to this, companies are actively investing in research activities to develop new testing methods for an accurate diagnosis. The commercial availability of immunochromatographic tests (ICT) all over the world is considered to create lucrative growth opportunities in this market. This testing technique is one of the most sensitive, affordable, and user-friendly advanced method of diagnosis which can provide results within 15–20 minutes.
Rising U.S. FDA approved testing kits is projected to further fuel market development. For instance, in May 2019, the U.S. FDA approved two tests that can detect the presence of Neisseria gonorrhoeae and bacteria Chlamydia trachomatis. The Xpert CT/NG and Aptima Combo 2 Assay are the two devices cleared by the regulatory body for extragenital diagnostic testing via the rectum and throat. In addition, other factors such as favorable government initiatives, growing awareness, and knowledge of sexual diseases coupled with new drug discoveries will support the overall market growth. Conversely, lack of awareness in the developing regions is predicted to impede the industry growth to some extent.
Types Takeaway
Depending upon types, the worldwide STD Diagnostics market is categorized into Syphilis, Chlamydia, Gonorrhea, Chancroid, Herpes Simplex Virus, Human Immunodeficiency Virus, and Human Papilloma Virus testing. Out of these, the Chlamydia testing category accounted for the highest revenue share, over 34% share in 2019. Chlamydia is the most commonly occurring STDs and can be treated by antibiotic medications such as erythromycin and azithromycin. In addition, a rise in the prevalence of this infection among pregnant women is anticipated to increase the rate of chlamydia screening, supporting the segment growth.
On the other hand, Syphilis screening is projected to grow with the fastest growth rate during the study period. As per the Centers for Disease Control and Prevention (CDC), there were more than 115,000 reported new diagnoses of all stages of syphilis in the U.S. alone and the number is increasing. The growing rate of anonymous sex, rising number of unprotected sex, sex with multiple partners and under the influence of several therapeutics will support the growth this category.
Testing Device Takeaway
In terms of testing devices, the overall industry is broadly bifurcated into laboratory, and point of care devices. The laboratory devices are further divided into flow cytometers, thermal cyclers – PCR, differential light scattering machines, lateral flow readers – immune-chromatographic assays, and absorbance microplate reader- enzyme-linked immune-sorbent assay (ELISA). Of the laboratory devices, the Lateral Flow Readers category held the highest, over 26%, revenue share in 2019.
Point of care (POC) devices are sub-divided into portable/rapid diagnostic kits, and phone chips (microfluidics + ICT). Among these rapid diagnostic kits accounted for the significant share and is projected to grow with promising CAGR during the forecast period. The integration of advanced technologies, coupled with the growing demand for rapid screening support the segment growth.
Testing Location Takeaway
Based on the testing location, the worldwide STD diagnostics market is divided into PoC, and laboratory testing (private labs, and public health labs). Currently, the laboratory segment captured maximum revenue share owing to the growing number of laboratories, offering STD screening. However, PoCs are anticipated to expand at the fastest growth rate due to its associated benefits compared to laboratories.
Regional Takeaway
Regionally, the overall market is viewed as North America, Middle East & Africa, Asia Pacific, Latin America, and Europe. North America is a dominating region for STD diagnostics owing to the rising prevalence of this infection coupled with favorable government policies for market development. As per the study of the National Center for Biotechnology Information (NCBI), in the U.S. only, more than 20 million sexually transmitted infections (STIs) occur every year and more than half of the cases occur between 15–24 year age group. In addition, advancement in technologies to improve the diagnosis & treatment of STD disorders would, in turn, support the regional growth to some extent.
On the flip side, the Asia Pacific region is the fastest-growing market, expanding at over 12% CAGR throughout the study scope. The rapid increase in the prevalence of sexual disorders, coupled with increasing government funding and programs are contributing to the APAC market growth.
COVID-19 Impact
The STD diagnostics market has moderately affected due to the outbreak of COVID-19 all over the globe. The diagnosis of this infection is conducted with special care, similar as the testing of the coronavirus in the patient. Thus, many governments have developed a certain guidelines for avoiding close contact and provided the social distancing rule. Thus, highlighting important developments in the STD Diagnostics field, which are relevant to the current pandemic will help the global market to sustain in the near future.
Key Vendor Takeaway
The leading players of the global STD Diagnostics market include Roche Diagnostics, Danaher Corporation, BioMerieux, Abbott Laboratories, Becton Dickinson and Company, Affymetrix, Inc., Cepheid, Inc., Hologic, Inc., DiaSorin, and Orasure.
Companies are actively involved in strategic mergers and acquisitions to capture a large customer base. In Dec 2017 Becton, Dickinson, and Company has been acquired C. R. Bard, Inc to become the global leader in the process of care for health care and providing treatment of various diseases for patients. This acquisition helped the company to obtain a strong position in the global industry.
The market size and forecast for each segment and sub-segments has been considered as below:
Historical Year – 2015 to 2018
Base Year – 2019
Estimated Year – 2020
Projected Year – 2026
TARGET AUDIENCE
Traders, Distributors, and Suppliers
Manufacturers
Government and Regional Agencies
Research Organizations
Consultants
Distributors
SCOPE OF THE REPORT
The scope of this report covers the market by its major segments, which include as follows:
GLOBAL SEXUALLY TRANSMITTED DISEASE (STD) DIAGNOSTICS MARKET KEY PLAYERS
Becton Dickinson and Company
Roche Diagnostics
Orasure
Hologic, Inc.
Cepheid Inc.
DiaSorin
Abbott Laboratories
Danaher Corporation
BioMerieux
Affymetrix, Inc.
GLOBAL SEXUALLY TRANSMITTED DISEASE (STD) DIAGNOSTICS MARKET, BY TYPES
Gonorrhea testing
Herpes Simplex Virus testing
Human Papilloma Virus testing
Human Immunodeficiency Virus testing
Chlamydia testing
Syphilis testing
Chancroid testing
Others
GLOBAL SEXUALLY TRANSMITTED DISEASE (STD) DIAGNOSTICS MARKET, BY TESTING DEVICE TYPE
Laboratory Devices
Thermal Cyclers – PCR
Lateral Flow Readers – Immunochromatographic assays
Flow Cytometers
Differential Light Scattering machines
Absorbance microplate reader – Enzyme-Linked Immunosorbent Assay (ELISA)
Others
Point of Care (PoC) Devices
Phone chips (microfluidics + ICT)
Portable/benchtop/rapid diagnostic kits
GLOBAL SEXUALLY TRANSMITTED DISEASE (STD) DIAGNOSTICS MARKET, BY TESTING LOCATION
Point of Care (POC) testing
Laboratory Testing
Commercial/Private labs
Public Health Labs
GLOBAL SEXUALLY TRANSMITTED DISEASE (STD) DIAGNOSTICS MARKET, BY REGION
North America
The U.S.
Canada
Europe
Germany
France
Italy
Spain
United Kingdom
Rest of Europe
Asia Pacific
India
China
South Korea
Japan
Singapore
Rest of APAC
Latin America
Brazil
Mexico
Argentina
Rest of LATAM
The Middle East and Africa
Saudi Arabia
United Arab Emirates
Rest of MEA